Eledon Pharmaceuticals, Inc. (ELDN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.76
- As of
Kresmion compiles this page from ELDN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Eledon Pharmaceuticals, Inc. (ELDN): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
See the full ELDN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ELDN on one page. Preview it with sample data, then open it live with a free account.
Preview the ELDN dossierActive events for ELDN
- high13F: funds added
5 tracked funds increased ELDN this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 67.5%, EPS $-0.27 vs $-0.1612 estimate
- high13F: funds added
4 tracked funds increased ELDN this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +822% to ELDN (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +613% to ELDN (2026Q2)
FREE, NO ACCOUNT
Every event on ELDN, as it fires
You are seeing 5 of 15 events recorded on ELDN since 2026-06-10.
The five above landed across 3 days. The other 10 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ELDN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 28617K101 · 2026Q2 | $3.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 28617K101 · 2026Q2 | $851K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 28617K101 · 2026Q2 | $792K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 28617K101 · 2026Q2 | $130K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ELDN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ELDN against its peers
ELDN's return on equity of -56.3% ranks in the 41st percentile of 22 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ELDN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 13.4M | n/a | 18 |
| Gross margin | n/a | 73.5% | n/a | 8 |
| Operating margin | n/a | -604.5% | n/a | 20 |
| Net margin | n/a | -276.7% | n/a | 20 |
| Return on equity | -56.3% | -48.3% | 41 | 22 |
Peers (24): RNAC, YARW, CGEN, DTIL, WHWK, EVMN, PRQR, NAGE, SION, XGN, ACOG, IVVD, KRRO, PYXS, PEPG, ORMP, TRDA, ALEC, PLX, CAMP, BBOT, IPHA, ADAG, ALXO. Left out: SCNLD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ELDN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ELDN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ELDN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.